Skip to Content
  • Review
  • Open Access

18 February 2020

26 Pages

Autoantibody Biomarkers in Rheumatic Diseases

,
and
1
Division of Rheumatology Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea
2
Department of Internal Medicine, Seoul National University, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Discovery of Antibody Biomarker

Abstract

Autoantibodies encountered in patients with systemic rheumatic diseases bear clinical significance as a biomarker to help or predict diagnosis, clinical phenotypes, prognosis, and treatment decision-making. Furthermore, evidence has accumulated regarding the active involvement of disease-specific or disease-associated autoantibodies in the pathogenic process beyond simple association with the disease, and such knowledge has become essential for us to better understand the clinical value of autoantibodies as a biomarker. This review will focus on the current update on the autoantibodies of four rheumatic diseases (rheumatoid arthritis, myositis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody associated vasculitis) where there has been a tremendous progress in our understanding on their biological effects and clinical use.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.